-
1
-
-
80455140368
-
Ulcerative colitis
-
1 Danese, S., Fiocchi, C., Ulcerative colitis. N Engl J Med 365 (2011), 1713–1725.
-
(2011)
N Engl J Med
, vol.365
, pp. 1713-1725
-
-
Danese, S.1
Fiocchi, C.2
-
2
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
2 Rutgeerts, P., Sandborn, W.J., Feagan, B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005), 2462–2476.
-
(2005)
N Engl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
-
3
-
-
84856163835
-
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis
-
3 Sandborn, W.J., van Assche, G., Reinisch, W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142 (2012), 257–265.
-
(2012)
Gastroenterology
, vol.142
, pp. 257-265
-
-
Sandborn, W.J.1
van Assche, G.2
Reinisch, W.3
-
4
-
-
84890620601
-
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis
-
4 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 85–95.
-
(2014)
Gastroenterology
, vol.146
, pp. 85-95
-
-
Sandborn, W.J.1
Feagan, B.G.2
Marano, C.3
-
5
-
-
84890629055
-
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis
-
5 Sandborn, W.J., Feagan, B.G., Marano, C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146 (2014), 96–109.
-
(2014)
Gastroenterology
, vol.146
, pp. 96-109
-
-
Sandborn, W.J.1
Feagan, B.G.2
Marano, C.3
-
6
-
-
84881187537
-
Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials
-
6 Ford, A.C., Peyrin-Biroulet, L., Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108 (2013), 1268–1276.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. 1268-1276
-
-
Ford, A.C.1
Peyrin-Biroulet, L.2
-
7
-
-
84863724798
-
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease
-
7 Lichtenstein, G.R., Rutgeerts, P., Sandborn, W.J., et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 107 (2012), 1051–1063.
-
(2012)
Am J Gastroenterol
, vol.107
, pp. 1051-1063
-
-
Lichtenstein, G.R.1
Rutgeerts, P.2
Sandborn, W.J.3
-
8
-
-
70349086185
-
The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases
-
8 Soler, D., Chapman, T., Yang, L.L., et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 330 (2009), 864–875.
-
(2009)
J Pharmacol Exp Ther
, vol.330
, pp. 864-875
-
-
Soler, D.1
Chapman, T.2
Yang, L.L.3
-
9
-
-
84929773619
-
Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
-
9 Wyant, T., Estevam, J., Yang, L., et al. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 90 (2016), 168–176.
-
(2016)
Cytometry B Clin Cytom
, vol.90
, pp. 168-176
-
-
Wyant, T.1
Estevam, J.2
Yang, L.3
-
10
-
-
84867576762
-
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
-
10 Fedyk, E.R., Wyant, T., Yang, L.L., et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 18 (2012), 2107–2119.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 2107-2119
-
-
Fedyk, E.R.1
Wyant, T.2
Yang, L.L.3
-
11
-
-
84874280106
-
Antagonizing the α4β7 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis
-
11 Haanstra, K.G., Hofman, S.O., Lopes Estevao, D.M., et al. Antagonizing the α4β7 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol 190 (2013), 1961–1973.
-
(2013)
J Immunol
, vol.190
, pp. 1961-1973
-
-
Haanstra, K.G.1
Hofman, S.O.2
Lopes Estevao, D.M.3
-
12
-
-
0029826678
-
Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7
-
12 Hesterberg, P.E., Winsor-Hines, D., Briskin, M.J., et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 111 (1996), 1373–1380.
-
(1996)
Gastroenterology
, vol.111
, pp. 1373-1380
-
-
Hesterberg, P.E.1
Winsor-Hines, D.2
Briskin, M.J.3
-
13
-
-
84886788747
-
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
-
13 Milch, C., Wyant, T., Xu, J., et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 264 (2013), 123–126.
-
(2013)
J Neuroimmunol
, vol.264
, pp. 123-126
-
-
Milch, C.1
Wyant, T.2
Xu, J.3
-
14
-
-
85009355752
-
Entyvio (vedolizumab)
-
[package insert] Takeda Pharmaceuticals America, Inc. Deerfield, IL
-
14 Takeda, Entyvio (vedolizumab). [package insert], 2014, Takeda Pharmaceuticals America, Inc., Deerfield, IL.
-
(2014)
-
-
Takeda1
-
15
-
-
84882769357
-
Vedolizumab as induction and maintenance therapy for ulcerative colitis
-
15 Feagan, B.G., Rutgeerts, P., Sands, B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369 (2013), 699–710.
-
(2013)
N Engl J Med
, vol.369
, pp. 699-710
-
-
Feagan, B.G.1
Rutgeerts, P.2
Sands, B.E.3
-
16
-
-
69049110950
-
Confidence interval or p-value? Part 4 of a series on evaluation of scientific publications
-
16 du Prel, J.B., Hommel, G., Rohrig, B., et al. Confidence interval or p-value? Part 4 of a series on evaluation of scientific publications. Dtsch Arztebl Int 106 (2009), 335–339.
-
(2009)
Dtsch Arztebl Int
, vol.106
, pp. 335-339
-
-
du Prel, J.B.1
Hommel, G.2
Rohrig, B.3
-
17
-
-
0032991290
-
The medical dictionary for regulatory activities (MedDRA)
-
17 Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999), 109–117.
-
(1999)
Drug Saf
, vol.20
, pp. 109-117
-
-
Brown, E.G.1
Wood, L.2
Wood, S.3
-
18
-
-
84960145681
-
The safety of vedolizumab for ulcerative colitis and Crohn's disease
-
[Epub ahead of print]
-
18 Colombel, J.F., Sands, B.E., Rutgeerts, P., et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2016 [Epub ahead of print].
-
(2016)
Gut
-
-
Colombel, J.F.1
Sands, B.E.2
Rutgeerts, P.3
-
19
-
-
84869456003
-
Strategies for the care of adults hospitalized for active ulcerative colitis
-
19 Pola, S., Patel, D., Ramamoorthy, S., et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 10 (2012), 1315–1325 e4.
-
(2012)
Clin Gastroenterol Hepatol
, vol.10
, pp. 1315-1325 e4
-
-
Pola, S.1
Patel, D.2
Ramamoorthy, S.3
-
20
-
-
34347402306
-
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
-
20 Sandborn, W.J., Rutgeerts, P., Enns, R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007), 829–838.
-
(2007)
Ann Intern Med
, vol.146
, pp. 829-838
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Enns, R.3
-
21
-
-
84864714487
-
Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease
-
21 de Silva, P.S., Nguyen, D.D., Sauk, J., et al. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 36 (2012), 459–466.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 459-466
-
-
de Silva, P.S.1
Nguyen, D.D.2
Sauk, J.3
-
22
-
-
84899061007
-
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease
-
22 Rubin, D.T., Mody, R., Davis, K.L., et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 39 (2014), 1143–1155.
-
(2014)
Aliment Pharmacol Ther
, vol.39
, pp. 1143-1155
-
-
Rubin, D.T.1
Mody, R.2
Davis, K.L.3
-
23
-
-
79953788656
-
Assessing response and loss of response to biological therapies in IBD
-
23 Yanai, H., Hanauer, S.B., Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 106 (2011), 685–698.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 685-698
-
-
Yanai, H.1
Hanauer, S.B.2
-
24
-
-
85033597671
-
Optimizing the use of biological therapy in patients with inflammatory bowel disease
-
24 Moss, A.C., Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf) 3 (2015), 63–68.
-
(2015)
Gastroenterol Rep (Oxf)
, vol.3
, pp. 63-68
-
-
Moss, A.C.1
-
25
-
-
84855648247
-
Therapeutic drug monitoring of biologics for inflammatory bowel disease
-
25 Colombel, J.F., Feagan, B.G., Sandborn, W.J., et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 18 (2012), 349–358.
-
(2012)
Inflamm Bowel Dis
, vol.18
, pp. 349-358
-
-
Colombel, J.F.1
Feagan, B.G.2
Sandborn, W.J.3
-
26
-
-
77951974444
-
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease
-
26 Afif, W., Loftus, E.V. Jr., Faubion, W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105 (2010), 1133–1139.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1133-1139
-
-
Afif, W.1
Loftus, E.V.2
Faubion, W.A.3
-
27
-
-
84904727989
-
Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 [abstract]
-
27 Rosario, M., Fox, I., Milch, C., et al. Pharmacokinetic/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 [abstract]. Inflamm Bowel Dis, 19(Suppl 1), 2013, 140.
-
(2013)
Inflamm Bowel Dis
, vol.19
, pp. 140
-
-
Rosario, M.1
Fox, I.2
Milch, C.3
-
28
-
-
77950988234
-
Infliximab, azathioprine, or combination therapy for Crohn's disease
-
28 Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362 (2010), 1383–1395.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
-
29
-
-
84899998067
-
Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy
-
29 Subramaniam, K., Richardson, A., Dodd, J., et al. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Intern Med J 44 (2014), 464–470.
-
(2014)
Intern Med J
, vol.44
, pp. 464-470
-
-
Subramaniam, K.1
Richardson, A.2
Dodd, J.3
-
30
-
-
84881542095
-
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
-
30 Garcia-Bosch, O., Gisbert, J.P., Canas-Ventura, A., et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 7 (2013), 717–722.
-
(2013)
J Crohns Colitis
, vol.7
, pp. 717-722
-
-
Garcia-Bosch, O.1
Gisbert, J.P.2
Canas-Ventura, A.3
-
31
-
-
84900550345
-
Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis
-
31 Hayes, M.J., Stein, A.C., Sakuraba, A., Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. J Gastroenterol Hepatol 29 (2014), 1177–1185.
-
(2014)
J Gastroenterol Hepatol
, vol.29
, pp. 1177-1185
-
-
Hayes, M.J.1
Stein, A.C.2
Sakuraba, A.3
-
32
-
-
84892737455
-
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis
-
32 Panaccione, R., Ghosh, S., Middleton, S., et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146 (2014), 392–400 e3.
-
(2014)
Gastroenterology
, vol.146
, pp. 392-400 e3
-
-
Panaccione, R.1
Ghosh, S.2
Middleton, S.3
-
33
-
-
84929908673
-
Which patients with inflammatory bowel disease should receive combination therapy?
-
33 Cross, R.K., Which patients with inflammatory bowel disease should receive combination therapy?. Expert Rev Gastroenterol Hepatol 9 (2015), 715–717.
-
(2015)
Expert Rev Gastroenterol Hepatol
, vol.9
, pp. 715-717
-
-
Cross, R.K.1
-
34
-
-
84887210548
-
Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease
-
34 Orlando, A., Guglielmi, F.W., Cottone, M., et al. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Dig Liver Dis 45 (2013), 986–991.
-
(2013)
Dig Liver Dis
, vol.45
, pp. 986-991
-
-
Orlando, A.1
Guglielmi, F.W.2
Cottone, M.3
-
35
-
-
84930015437
-
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease
-
35 Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148 (2015), 1320–1329.
-
(2015)
Gastroenterology
, vol.148
, pp. 1320-1329
-
-
Vande Casteele, N.1
Ferrante, M.2
Van Assche, G.3
-
36
-
-
84894640694
-
Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives
-
36 Vande Casteele, N., Feagan, B.G., Gils, A., et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep, 16, 2014, 378.
-
(2014)
Curr Gastroenterol Rep
, vol.16
, pp. 378
-
-
Vande Casteele, N.1
Feagan, B.G.2
Gils, A.3
-
37
-
-
79751472562
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
-
quiz 3
-
37 D'Haens, G.R., Panaccione, R., Higgins, P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 106 (2011), 199–212 quiz 3.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 199-212
-
-
D'Haens, G.R.1
Panaccione, R.2
Higgins, P.D.3
-
38
-
-
84886946831
-
Optimizing anti-TNF treatments in inflammatory bowel disease
-
38 Ben-Horin, S., Kopylov, U., Chowers, Y., Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13 (2014), 24–30.
-
(2014)
Autoimmun Rev
, vol.13
, pp. 24-30
-
-
Ben-Horin, S.1
Kopylov, U.2
Chowers, Y.3
|